Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 6/2012

01-06-2012 | Case Report

Azathioprine Induced Liver Injury: A Case Report

Authors: Narendra S. Choudhary, Sachin Gupta, Yogesh K. Chawla, Ajay Duseja, Radha K. Dhiman, Ashim Das

Published in: Digestive Diseases and Sciences | Issue 6/2012

Login to get access

Excerpt

Azathioprine is used commonly in clinical practice for various autoimmune diseases. It is known to cause multiple adverse effects including hepatotoxicity. Azathioprine-induced liver injury is rare in clinical practice but can manifest in several ways. …
Literature
1.
Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis. 2007;11:477–505.PubMedCrossRef
2.
Mion F, Napoleon B, Berger F, Chevallier M, Bonvoisin S, Descos L. Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis. Gut. 1991;32:715–717.PubMedCrossRef
3.
Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806–815.PubMedCrossRef
4.
5.
Sobesky R, Dusoleil A, Condat B, Bedossa P, Buffet C, Pelletier G. Azathioprine-induced destructive cholangitis. Am J Gastroenterol. 2001;96:616–617.PubMedCrossRef
6.
Cattan S, Wendum D, Chazouilleres O, Schmitz J, Gendre JP. Hepatocellular carcinoma and focal hepatic glycogenosis after prolonged azathioprine therapy. Hum Pathol. 2000;31:874–876.PubMedCrossRef
7.
Russmann S, Zimmermann A, Krähenbühl S, Kern B, Reichen J. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol. 2001;13:287–290.PubMedCrossRef
8.
Gisbert JP, González-Lama Y, Maté J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2007;102:1518–1527.PubMedCrossRef
9.
Bastida G, Nos P, Aguas M, et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;1:775–782.CrossRef
Metadata
Title
Azathioprine Induced Liver Injury: A Case Report
Authors
Narendra S. Choudhary
Sachin Gupta
Yogesh K. Chawla
Ajay Duseja
Radha K. Dhiman
Ashim Das
Publication date
01-06-2012
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2012
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2056-0

Other articles of this Issue 6/2012

Digestive Diseases and Sciences 6/2012 Go to the issue

Original Article

Impairment of Gastric Nitrergic and NRF2 System in Apolipoprotein E Knockout Mice

Perspective

Time to Rethink Antiviral Treatment for Hepatitis C in Patients with Coexisting Mental Health/Substance Abuse Issues

Original Article

Liver Stiffness Measurement Using Acoustic Radiation Force Impulse (ARFI) Elastography and Effect of Necroinflammation

Editorial

Is Diabetes a Risk Factor for Colorectal Cancer?

Original Article

Clinical Characteristics and the Expression Profiles of Inflammatory Cytokines/Cytokine Regulatory Factors in Asymptomatic Patients with Nodular Gastritis

Stanford Multidisciplinary Seminars

Abdominal Mass, Anemia, Diabetes Mellitus, and Necrolytic Migratory Erythema
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits